FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP decided that Lysodren's benefits are greater than its risks for the treatment of advanced adrenal cortical carcinoma, but noted that the effect of Lysodren has not been established in adrenal cortical carcinoma that is not producing high levels of steroid hormones.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Lysodren huma akbar mir-riskji tiegħu għat-trattament ta' karċinoma avvanzata tal-kortiċi adrenali, iżda nnota li l-effett ta' Lysodren ma ġiex stabbilit f'karċinoma tal-kortiċi adrenali li ma tkunx qiegħda tipproduċi livelli għoljin ta' ormoni tal-isterojdi.
English: It presented the results of 220 studies published since 1990 on the use of the medicine in unresectable, metastatic adrenal cortical carcinoma.
Maltese: Hija ppreżentat ir-riżultati ta' 220 studju ppubblikati mill-1990 'l hawn dwar l-użu ta' din il-mediċina f'karċinoma metastatika tal-kortiċi adrenali li ma tistax titneħħa b'intervent kirurġiku.
English: What is Lysodren?
Maltese: X'inhu Lysodren?
English: What is the risk associated with Lysodren?
Maltese: X'inhu r-riskju assoċjat ma' Lysodren?
English: The studies included over 500 adults and children, who were treated for various lengths of time with mitotane, either alone or in combination with other anticancer medicines.
Maltese: L-istudji kienu jinkludu 'l fuq minn 500 adult u tfal, li ġew ikkurati għal diversi tulijiet ta' żmien b'mitotane, jew waħdu jew flimkien ma' mediċini oħra kontra l-kanċer.
English: Since the active substance in Lysodren, mitotane, is a well-established medicine that has been used in the treatment of adrenal cortical carcinoma in Europe since 1959, the company presented information from the published literature to support its application for Lysodren.
Maltese: Peress li s-sustanza attiva f'Lysodren, il-mitotane, hija mediċina stabbilita sewwa li ilha tintuża fittrattament ta' karċinoma tal-kortiċi adrenali fl-Ewropa mill-1959, il-kumpanija ppreżentat informazzjoni mil-letteratura ppubblikata biex issostni l-applikazzjoni tagħha għal Lysodren.
English: The recommended starting dose in adults is 2 to 3 g per day, divided into two or three doses, taken with meals containing fatty food.
Maltese: Id-doża tal-bidu rakkomandata fl-adulti hija 2 sa 3 grammi kuljum, maqsuma f'żewġ jew tliet dożi, meħuda ma' ikliet li fihom ikel xaħmi.
English: For the full list of all side effects reported with Lysodren, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji kollha rrappurtati b'Lysodren, ara l-fuljett ta' tagħrif.
English: How has Lysodren been studied?
Maltese: Kif ġie studjat Lysodren?
English: This overview was last updated in 11-2018.
Maltese: Din il-ħarsa ġenerali ġiet aġġornata l-aħħar f'11-2018.
English: Further information on Afinitor can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Afinitor.
Maltese: ema.europa.eu/medicines/human/EPAR/Afinitor.
English: Afinitor contains the active substance everolimus.
Maltese: Afinitor fih is-sustanza attiva everolimus.
English: Other information about Afinitor
Maltese: Informazzjoni oħra dwar Afinitor
English: Afinitor is available as tablets (2.5, 5 and 10 mg) and the recommended dose is 10 mg once a day.
Maltese: Afinitor jiġi bħala pilloli (2.5, 5 u 10 mg) u d-doża tal-bidu rakkomandata hija 10 mg darba kuljum.
English: The most common side effects with Afinitor (which may affect more than 1 in 10 people) are rash, itching, nausea, decreased appetite, dysgeusia (taste disturbances), headache, weight loss, peripheral oedema (swelling, especially of the ankles and feet), cough, anaemia (low red blood cell counts), tiredness, diarrhoea, weakness, infections, stomatitis (inflammation of the lining of the mouth), hyperglycaemia (high blood glucose levels), hypercholesterolaemia (high blood cholesterol levels), pneumonitis (inflammation of the lungs) and nosebleeds.
Maltese: L-effetti sekondarji l-aktar komuni b'Afinitor (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma raxx, ħakk, nawżja, tnaqqis fl-aptit, disgweżja (disturbi fit-togħma), uġigħ ta' ras, tnaqqis fil-piż, edema periferika (nefħa, l-aktar tal-għekiesi u s-saqajn), sogħla, anemija (għadd baxx taċ-ċelloli ħomor tad-demm), għeja, dijarrea, debbolezza, infezzjonijiet, stomatite (infjammazzjoni tal-kisi talħalq), ipergliċemija (livelli għoljin ta' glukożju fid-demm), iperkolesterolemija (livelli għoljin ta' kolesterol fid-demm), pnewmonite (infjammazzjoni tal-pulmuni) u fsada mill-imnieħer.
English: The active substance in Afinitor, everolimus, blocks an enzyme called ‘mammalian target of rapamycin' (mTOR).
Maltese: Is-sustanza attiva f'Afinitor, l-everolimus, timblokka enzima msejħa “mira tar-rapamiċina filmammiferi” (mTOR - mammalian target of rapamycin).
English: Pancreatic neuroendocrine tumours
Maltese: Tumuri newroendokrinali pankreatiċi
English: What are the risks associated with Afinitor?
Maltese: X'inhuma r-riskji assoċjati ma' Afinitor?
English: Afinitor received a marketing authorisation valid throughout the EU on 03 August 2009.
Maltese: Afinitor ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-3 ta' Awwissu 2009.
English: • pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) when the cancer cells are well- or moderately differentiated (which means that they can be distinguished from normal pancreas cells).
Maltese: • tumuri newroendokrinali pankreatiċi (tumuri taċ-ċelloli li jipproduċu l-ormoni fil-frixa) meta ċ-ċelloli tal-kanċer ikunu differenzjati tajjeb jew b'mod moderat (li jfisser li jistgħu jiġu distinti minn ċelloli normali tal-frixa).
English: Renal cell carcinoma
Maltese: Karċinoma taċ-ċellola renali
English: Afinitor is used in breast cancer that is ‘hormone receptor-positive' (when the cancer cells have oestrogen receptors on their surface) and ‘HER2/neu negative' (when the cancer cells do not contain high levels of the HER2/neu [human epidermal growth factor receptor-2] protein).
Maltese: Afinitor jintuża f'kanċer tas-sider li huwa “pożittiv għar-riċetturi tal-ormon” (meta ċ-ċelloli tal-kanċer ikollhom ir-riċetturi tal-estroġenu fil-wiċċ) u ‘HER2/neu negattiv' (meta ċ-ċelloli tal-kanċer ma jkollhomx livelli għolja tal-proteina HER2/neu [fattur tat-tkabbir epidermali tar-riċettur-2 uman]).
English: • advanced renal cell carcinoma (a kidney cancer), when the cancer has worsened despite treatment with a ‘VEGF-targeted' medicine (a type of medicine that blocks the effects of vascular endothelial growth factor proteins).
Maltese: • karċinoma avvanzata f'ċelloli renali (kanċer tal-kliewi), meta l-kanċer ikun iggrava minkejja l-kura b'mediċina “mmirata lejn VEGF” (‘VEGF-targeted' medicine - tip ta' mediċina li timblokka l-effetti tal-proteini ta' fattur tat-tkabbir tal-endotilju vaskulari).
English: Afinitor slowed down disease progression in patients with advanced neuroendocrine tumours of pancreatic origin, advanced renal cell carcinoma and hormone-receptorpositive advanced breast cancer.
Maltese: Afinitor naqqas il-progressjoni tal-marda f'pazjenti b'tumuri newroendokrinali avvanzati ta' oriġini pankreatika, b'karċinoma avvanzata taċ-ċellola renali u b'kanċer tas-sider avvanzat pożittiv għar-riċetturi tal-ormon.
English: Afinitor in combination with exemestane has been studied in 724 patients with hormone receptorpositive and HER2/neu-negative advanced breast cancer which had got worse after treatment with letrozole and anastrazole (non-steroidal aromatase inhibitors).
Maltese: Afinitor f'kombinazzjoni ma' eksemestan ġie studjat f'724 pazjent b'kanċer tas-sider avvanzat pożittiv għar-riċettur tal-ormon u HER2/neu-negattiv li qaleb għall-agħar wara l-kura b'letrożol u b'anastrażol (inibituri aromatażi nonsterojdali).
English: A study in 410 patients with advanced well- or moderately differentiated neuroendocrine tumours of pancreatic origin compared Afinitor with placebo.
Maltese: Studju f'410 pazjenti b'tumuri newroendokrinali differenzjati tajjeb jew b'mod moderat ta' oriġini pankreatikali qabbel Afinitor ma' plaċebo.
English: In the body, everolimus first attaches to a protein called FKBP-12 that is found inside cells to make a ‘complex'.
Maltese: Fil-ġisem, l-everolimus l-ewwel teħel ma' proteina msejħa FKBP-12 li tinsab fiċ-ċelloli biex tifforma “kumpless”.
English: Afinitor is used together with a medicine called exemestane after other treatments called ‘nonsteroidal aromatase inhibitors' have not worked;
Maltese: Afinitor jintuża flimkien ma' mediċina msejħa eksemestan wara li kuri oħra msejħa “inibituri aromatażi nonsterojdali” jkunu fallew;
English: Afinitor must not be used in people who are hypersensitive (allergic) to other rapamycin derivatives (substances with a similar structure to everolimus) or to any of the other ingredients.
Maltese: Afinitor ma għandux jintuża f'persuni li huma ipersensittivi (allerġiċi) għal derivati oħrajn tarrapamiċina (sustanzi bi struttura simili għal everolimus) jew għal kwalunkwe ingredjent ieħor tiegħu.
English: As for all medicines, data on the use of Afinitor are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Afinitor hija ssorveljata kontinwament.
English: This complex then blocks mTOR.
Maltese: Dan il-kumpless imbagħad jimblokka l-mTOR.
English: How does Afinitor work?
Maltese: Kif jintuża Afinitor?
English: Afinitor was studied in 302 patients with advanced neuroendocrine tumours of lung or gut origin.
Maltese: Afinitor ġie studjat fi 302 pazjenti b'tumuri newroendokrinali avvanzati li joriġinaw mill-pulmun jew mill-musrana.
English: How is Afinitor used?
Maltese: Kif jaħdem Afinitor?
English: Patients who took Afinitor lived for an average of 4.9 months without the disease getting worse, compared with 1.9 months for the patients who took placebo.
Maltese: Il-pazjenti li ħadu Afinitor għexu għal medja ta' 4.9 xhur mingħajr ma l-marda marret għall-agħar, meta mqabbla ma' 1.9 xhur għall-pazjenti li ħadu l-plaċebo.
English: For the full list of side effects of Afinitor, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji ta' Afinitor, ara l-fuljett ta' tagħrif.
English: Patients who received Afinitor and best supportive treatments lived for an average of 11 months without the disease getting worse compared with around 4 months for patients who received placebo and best supportive treatments to relieve disease symptoms.
Maltese: Il-pazjenti li rċevew Afinitor u l-aħjar kuri ta' appoġġ għexu għal medja ta' 11-il xahar mingħajr ma l-marda marret għall-agħar meta mqabbla ma' madwar 4 xhur għall-pazjenti li ħadu lplaċebo u l-aħjar kuri ta' appoġġ biex itaffu s-sintomi tal-marda.
English: Patients who took Afinitor lived for an average of 11.0 months without the disease getting worse, compared with 4.6 months for the patients who took placebo.
Maltese: Il-pazjenti li ħadu Afinitor għexu medja ta' 11-il xahar mingħajr ma l-marda marret għall-agħar, meta mqabbla ma' 4.6 xhur għall-pazjenti li ħadu l-plaċebo.
English: Afinitor was studied in 416 patients with advanced renal cell carcinoma that had got worse despite treatment with VEGF-targeted medicines (sunitinib, sorafenib or both).
Maltese: Afinitor ġie studjat f'416-il pazjent b'karċinoma avvanzata taċ-ċellola renali li marret għall-agħar minkejja l-kura b'mediċini mmirati lejn VEGF (sunitinib, sorafenib jew it-tnejn).
English: Patients who took Afinitor lived for an average of 7.8 months without their disease getting worse, compared with 3.2 months for the patients who took placebo (a dummy treatment).
Maltese: Il-pazjenti li ħadu Afinitor għexu għal medja ta' 7.8 xhur mingħajr ma l-marda tagħhom marret għall-agħar, meta mqabbla ma' 3.2 xhur għall-pazjenti kkurati bil-plaċebo (kura finta).
English: Doses need to be reduced for patients with liver problems.
Maltese: Id-dożi jeħtieġ li jitnaqqsu f'pazjenti bi problemi fil-fwied.
English: EU/1/16/1116/001 Epclusa
Maltese: EU/1/16/1116/001
English: 400 mg / 100 mg Film-coated tablet
Maltese: 400 mg / 100 mg Pillola miksija b'rita
English: Invented name Strength
Maltese: Isem ivvintat
English: This medicinal product is authorised in the Member States of the EEA under the following names: Austria, Belgium, Bulgaria, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Luxemburg, Malta, Netherlands, Poland, Romania, Slovak Republic, Slovenia, Spain, Sweden, United Kingdom: Targocid
Maltese: L-Awstrija, Il-Belġju, Il-Bulgarija, Ir-Repubblika Ċeka, Id-Danimarka, Franza, Il-Ġermanja, Il-Greċja, LUngerija, L-Irlanda, Il-Lussemburgu, Malta, L-Olanda, Il-Polonja, Ir-Rumanija, Is-Slovakkja, Slovenja, Spanja, L-Isvezja, Ir-Renju Unit: Targocid
English: Targocid is an antibiotic.
Maltese: Targocid huwa antibijotiku.
English: Microorganism
Maltese: Mikroorganiżmu
English: • infective endocarditis,
Maltese: • endokardite infettiva,
English: • The active substance is teicoplanin.
Maltese: • Is-sustanza attiva hija teicoplanin.
English: Staphylococcus aureus (including methicillin-resistant strains) Streptococcus agalactiae
Maltese: Staphylococcus aureus (inkluż ir-razez reżistenti għall-methicillin) Streptococcus agalactiae
English: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Maltese: Komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000); rari ħafna (<1/10,000); mhux magħruf (ma tistax tittieħed stima mid-dejta disponibbli).
English: - Pneumonia
Maltese: - Pulmonite
English: 0.18% sodium chloride and 4% glucose solution 0.45% sodium chloride and 5% glucose solution Peritoneal dialysis solution containing 1.36% or 3.86% glucose solution.
Maltese: Soluzzjoni ta' 0.18% sodium chloride u 4% glucose Soluzzjoni ta' 0.45% sodium chloride u 5% glucose Soluzzjoni ta' dijalisi mill-peritonew li fiha soluzzjoni ta' 1.36% jew 3.86% ta' glucose.
English: Common (≥1/100 to
Maltese: Komuni (≥1/100 sa
English: - Infective endocarditis
Maltese: - Endokardite infettiva
English: • sodium chloride 9 mg/mL (0.9%) solution
Maltese: • soluzzjoni ta' sodium chloride 9 mg/mL (0.9%)
English: Fluorescence Polarization Immunoassay (FPIA) method.
Maltese: Fluworexxenti b'Polarizzazzjoni (FPIA - Fluorescence Polarization Immunoassay).
English: System organ class
Maltese: Klassi tassistemi u talorgani
English: • you are allergic to an antibiotic called ‘vancomycin'
Maltese: • inti allerġiku għal antibijotiku msejjaħ ‘vancomycin'
English: The final solution is isotonic with plasma and has a pH of 7.2-7.8.
Maltese: Is-soluzzjoni finali hija isotonika mal-plażma u għandha pH ta' 7.2-7.8.
English: Gram-positive anaerobes except Clostridium difficile PK/PD (Non-species related) breakpoints c,d
Maltese: Anaerobi Gram-positive minbarra Clostridium difficile breakpoints PK/PD (mhux marbuta mal-ispeċi) c,d
English: Two metabolites are formed probably by hydroxylation and represents 2 to 3% of the administered dose.
Maltese: Żewġ metaboliti jiġu ffurmati probabbilment b'idroksilazzjoni u jirrappreżentaw minn 2 sa 3% tad-doża mogħtija.
English: Transaminases increased (transient abnormality of transaminases), blood alkaline phosphatase increased (transient abnormality of alkaline phosphatase), blood creatinine increased (transient rise of serum creatinine)
Maltese: Żieda fittransaminases (anormalità temporanja tattransaminases), żieda fl-alkaline phosphatase fiddemm (anormalità temporanja talalkaline phosphatase), żieda fil-kreatinina fid-demm (żieda temporanja talkreatinina fisserum)
English: • Ringer-lactate solution
Maltese: • soluzzjoni Ringer-lactate
English: thrombocytopenia, eosinophilia
Maltese: Lewkopenija, tromboċitopenija, eosinofilja
English: • 0.45% sodium chloride and 5% glucose solution
Maltese: • soluzzjoni ta' 0.45% sodium chloride u 5% glucose
English: • 0.18% sodium chloride and 4% glucose solution
Maltese: • soluzzjoni ta' 0.18% sodium chloride u 4% glucose
English: • Peritoneal dialysis solution containing 1.36% or 3.86% glucose solution.
Maltese: • soluzzjoni ta' dijalisi mill-peritonew li fiha soluzzjoni ta' 1.36% jew 3.86% glucose.
English: Linearity Teicoplanin exhibited linear pharmacokinetics at dose range of 2 to 25 mg/kg.
Maltese: Linearità Teicoplanin wera farmakokinetika lineari fuq medda ta' doża minn 2 sa 25 mg/kg.
English: A number of vancomycin-resistant enterococci are sensitive to teicoplanin (Van-B phenotype).
Maltese: Numru ta' enterococci reżistenti għal vancomycin huma sensittivi għal teicoplanin (fenotip Van-B).
English: Stevens-Johnson syndrome, erythema multiforme, angioedema, dermatitis exfoliative, urticaria (see section
Maltese: Nekroliżi tossika talepidermide, Sindrome ta' StevensJohnson, eritema multiforme, anġjoedima, dematite li taqa' qxur qxur, urtikarja (ara sezzjoni
English: Uncommon (≥1/1,000 to
Maltese: Mhux komuni (≥1/1,000 sa
English: Anaphylactic reaction (anaphylaxis) (see section 4.4)
Maltese: Reazzjoni anafilattika (anafilassi) (ara sezzjoni 4.4)
English: The MICs breakpoints according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST), version 3.1, February 11, 2013 are displayed in the following table:
Maltese: Il-breakpoints tal-MICs skont il-Kumitat Ewropew dwar l-Ittestjar ta' Suxxettibilità Kontra l-Mikrobi (EUCAST - European Committee on Antimicrobial Susceptibility Testing) (EUCAST), verżjoni 3.1, 11 ta' Frar, 2013 huma murija fit-tabella li ġejja:
English: These include aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, and ethacrynic acid (see section 4.4).
Maltese: Dawn jinkludu aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, u ethacrynic acid (ara sezzjoni 4.4). Madankollu, ma hemm l-ebda xhieda ta' tossiċità sinerġetika f'kombinazzjonijiet ma' teicoplanin.
English: Commonly susceptible species Aerobic Gram-positive bacteria Corynebacterium jeikeium a
Maltese: Speċi suxxettibbli b'mod komuni Batterji aerobiċi Gram-positive Corynebacterium jeikeium a
English: Teicoplanin has a limited spectrum of antibacterial activity (Gram-positive).
Maltese: Teicoplanin għandu firxa limitata ta' attività kontra l-batterji (Gram-positive).
English: Pharmacotherapeutic group: Glycopeptide Antibacterials, ATC code: J01XA 02
Maltese: Antibatteriċi Glycopeptide, Kodiċi ATC:
English: Nominal teicoplanin content of vial
Maltese: Kontenut nominali ta' teicoplanin fil-kunjett
English: The volume of distribution at steady-state (Vss) varies from 0.7 to 1.4 mL/kg.
Maltese: Il-volum ta' distribuzzjoni fl-istat fiss (Vss) ivarja minn 0.7 sa 1.4 mL/kg.
English: Sodium hydroxide (for pH adjustment)
Maltese: Sodium hydroxide (għal aġġustament tal-pH)
English: Red man syndrome (e.g. Flushing of the upper part of the body) (see section 4.4).
Maltese: Red man syndrome (eż. Fwawar finnaħa ta' fuq tal-ġisem) (ara sezzjoni 4.4).
English: Unchanged form of teicoplanin is the main compound identified in plasma and urine, indicating minimal metabolism.
Maltese: Il-forma ta' teicoplanin mhux mibdula hija l-kompost prinċipali identifikat fil-plażma u fl-awrina, li tindika metaboliżmu minimu.
English: Primary packaging:
Maltese: Ippakkjar primarju:
English: The resistance breakpoint for S. aureus has been reduced to 2 mg/mL to avoid reporting of GISA isolates intermediate as serious infections with GISA isolates are not treatable with increased doses of vancomycin or teicoplanin.
Maltese: Il-breakpoint ta' reżistenza għal S. aureus tnaqqset għal 2 mg/mL biex jiġi evitat rappurtar ta' iżolati intermedji GISA minħabba li infezzjonijiet serji b'iżolati GISA ma jiġux ikkurati b'żieda fid-dożi ta' vancomycin jew teicoplanin.
English: Targeted trough concentrations at day 3 to 5
Maltese: L-aktar konċentrazzjonijiet baxxi mixtieqa filjiem 3 sa 5
English: Streptococci in the viridans group a b Anaerobic Gram-positive bacteria Clostridium difficile a
Maltese: Batterji anaerobiċi Gram-positive Clostridium difficile a
English: In pleural fluid and subcutaneous fat tissue the tissue/serum ratios are comprised between 0.2 and 0.5.
Maltese: Fil-fluwidu tal-plewra u t-tessut tax-xaħam ta' taħt il-ġilda ilproporzjonijiet fit-tessut/serum huma miżmuma fil-limiti bejn 0.2 u 0.5.
English: The reconstituted solutions will contain 100 mg of teicoplanin in 1.5 mL, 200 mg in 3.0 mL and 400 mg in 3.0 mL.
Maltese: Is-soluzzjonijiet rrikostitwiti jkun fihom 100 mg ta' teicoplanin f'1.5 mL, 200 mg fi 3.0 mL u 400 mg fi 3.0 mL.
English: Powder for solution for injection/infusion or oral solution Sodium chloride
Maltese: Trab għal soluzzjoni għall-injezzjoni/infużjoni jew soluzzjoni orali Sodium chloride
English: Ringer-lactate solution
Maltese: Soluzzjoni Ringer-lactate
English: Combination therapy
Maltese: Terapija kkombinata
English: Adults and elderly patients with normal renal function
Maltese: Adulti u pazjenti anzjani b'funzjoni normali tal-kliewi
English: Cross-resistance between teicoplanin and the glycoprotein vancomycin may occur.
Maltese: Tista' sseħħ reżistenza inkroċjata bejn teicoplanin u l-glikoproteina vancomycin.
English: Indications
Maltese: Indikazzjonijiet
English: • For endocarditis and other severe infections, teicoplanin trough levels of 15-30 mg/L when measured by HPLC, or 30-40 mg/L when measured by FPIA method.
Maltese: • Għal endokartite u infezzjonijiet qawwija oħra, l-aktar livelli baxxi ta' teicoplanin ta' 15-30 mg/L
English: Each vial contains either 100 mg, 200 mg or 400 mg teicoplanin.
Maltese: Kull kunjett fih 100 mg, 200 mg jew 400 mg teicoplanin.
English: For infective endocarditis a minimum of 21 days is usually considered appropriate.
Maltese: Għal endokardite infettiva issoltu huwa kkunsidrat xieraq minimu ta' 21 jum.
English: Renal failure (including renal failure acute)
Maltese: Insuffiċjenza tal-kliewi (inkluża insuffiċjenza akuta tal-kliewi)
English: Powder for solution for injection/infusion or oral solution also contains: sodium chloride, sodium hydroxide (for pH adjustment).
Maltese: Trab għal soluzzjoni għall-injezzjoni/infużjoni jew soluzzjoni orali fih ukoll: sodium chloride, sodium hydroxide (għal aġġustament tal-pH).
English: A higher total clearance (15.8 mL/h/kg for neonates, 14.8 mL/h/kg for a mean age 8 years) and a shorter elimination half-life (40 hours neonates; 58 hours for 8 years) are observed compared to adult patients.
Maltese: Tneħħija totali ogħla (15.8 mL/siegħa/kg għat-trabi tat-twelid, 14.8 mL/siegħa/kg għal età medja ta' 8 snin) u half-life ta' eliminazzjoni iqsar (40 siegħa għal trabi tat-twelid; 58 siegħa għall-età ta' 8 snin) huma osservati meta mqabbla mal-pazjenti adulti.
English: Susceptibility testing breakpoints
Maltese: Breakpoints tal-ittestjar ta' suxxettibilità
English: Practical information for healthcare professionals on preparation and handling of Targocid.
Maltese: Informazzjoni prattika għall-professjonisti fil-qasam mediku dwar il-preparazzjoni u limmaniġġjar ta' Targocid.
English: Life-threatening or even fatal cutaneous reactions Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported with the use of teicoplanin.
Maltese: Kienu rrappurtati reazzjonijiet tal-ġilda ta' periklu għall-ħajja u anke fatali tas-Sindrome ta' StevensJohnson (SJS - Stevens-Johnson syndrome) u Nekroliżi Tossika tal-Epidermide (TEN - Toxic Epidermal Necrolysis) bl-użu ta' teicoplanin.
English: The primary literature, standard volumes and treatment recommendations assume sensitivity b Collective term for a heterogeneous group of streptococcus species.
Maltese: Il-letteratura primarja, ilvolumi standard u r-rakkomandazzjonijiet tal-kura jassumu sensittività b Terminu kollettiv għal grupp eteroġenu ta' speċi ta' streptococcus.
English: Viridans group streptococci b
Maltese: Streptococci tal-grupp Viridans b
English: It is unlikely that your doctor or nurse will give you too much medicine.
Maltese: Mhuwiex probabbli li t-tabib jew l-infermier tiegħek jagħtuk wisq mediċina.
English: Species for which acquired resistance may be a problem Aerobic Gram-positive bacteria Enterococcus faecium
Maltese: Speċi li jista' jkollhom il-problema li jiksbu reżistenza Batterji aerobiċi Gram-positive Enterococcus faecium
English: 5% dextrose injection
Maltese: Injezzjoni ta' 5% dextrose
English: Thrombophlebitis
Maltese: Tromboċitopenija